Allianz Asset Management
URGN icon

Allianz Asset Management’s UroGen Pharma URGN Stock Holding History

Allianz Asset Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Hold
10,100
– – ﹤0.01% 2040
2026
Q1 		$182K Sell
10,100
-11,900
-54% -$239K ﹤0.01% 1945
2025
Q4 		$515K Hold
22,000
– – ﹤0.01% 1831
2025
Q3 		$439K Buy
22,000
+7,200
+49% +$129K ﹤0.01% 1868
2025
Q2 		$203K Buy
+14,800
New +$142K ﹤0.01% 1946

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Allianz Asset Management's URGN Position: Q2 2026 in Review

Allianz Asset Management held its UroGen Pharma (URGN) position steady in Q2 2026 at 10,100 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #2040.

Allianz Asset Management first reported a position in URGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $515K in Q4 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Allianz Asset Management held 10,100 shares of UroGen Pharma worth $182K as of Q2 2026.
  • Allianz Asset Management left its UroGen Pharma share count unchanged in Q2 2026.
  • UroGen Pharma made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #2040 holding.
  • Allianz Asset Management first reported a position in UroGen Pharma in Q2 2025 and has held it in 5 quarters since.
  • Allianz Asset Management's UroGen Pharma position peaked at $515K in Q4 2025.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.